12 High-Growth Micro-Cap Stocks to Buy Now

In this article, we will discuss the 12 High-Growth Micro-Cap Stocks to Buy Now.

Over the past few years, focus has been on large-cap stocks and the magnificent seven that have delivered spectacular returns. After three years of blockbuster gains, the trade is slowly coming under scrutiny amid concerns that markets are priced for perfection, with premium valuations in play.

Amid valuation concerns, a rotation away from large-cap stocks that have propelled the market to an all-time high is slowly brewing. Micro-cap stocks are increasingly showing extreme performance dispersion relative to the market. The cheap under-the-radar stocks are increasingly powering high, driven by innovation, niche industrial services, and specialized consumer segments.

Micro-caps tied to technological innovation and specialized consumer products have seen notable gains, as shown by the Russell Microcap index, which has rallied about 21% year to date. In contrast, the broader S&P 500 index has only gained 6% b over the same period.

Standing in the way of microcap and small-cap stocks rallying heading into year-end is growing concerns over the interest rate trajectory. Soaring inflation, driven by higher energy prices, has diminished the prospects of the US Federal Reserve cutting interest rates. Early in the year, David Royal, Thrivent Chief Financial & Investment Officer, warned that small companies would struggle without more interest rate cuts.

However, with the US appearing to have struck a deal with Iran, paving the way for the opening of the Strait of Hormuz, inflation could ease on energy flows, returning to normalcy. Inflation inching lower would make the case for lower interest rates, which would favor micro-cap stocks.

With that in mind, let’s take a look at the best high growth micro-cap stocks to buy now, likely to benefit from favorable macro conditions.

Our Methodology

To compile a list of the 12 High Growth Micro-Cap Stocks to Buy Now, we used Finviz and Yahoo Screener to scan for companies with a market cap of between $50 million and $300 million as of June 15. We also reviewed several micro‑cap growth stock ETFs, with the most notable being iShares Micro‑Cap ETF (IWC), First Trust Dow Jones Select MicroCap Index Fund (FDM), and Dimensional U.S. Micro Cap Portfolio ETF (DFMC). We trimmed the list to companies that have grown sales by over 10% over the past five years and are expected to grow earnings by over 20% over the same period. We also focused on stocks with upside potential of more than 20% and also detailed the number of hedge funds holding stakes in them in Q1 2026. Finally, we ranked the stocks in ascending order based on the number of hedge funds holding stakes in them.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

High-Growth Micro-Cap Stocks to Buy Now

12. Armata Pharmaceuticals Inc. (NYSE:ARMP)

Market Capitalization: $265.57 Million

Expected 5-Year Earnings Growth: 40.13%

Number of Hedge Fund Holders: 4

Stock Upside Potential: 130.87%

Armata Pharmaceuticals Inc. (NYSE:ARMP) is one of the high-growth micro-cap stocks to buy now. On May 7, Armata Pharmaceuticals Inc. (NYSE:ARMP) achieved a significant milestone when the U.S Food and Drug Administration granted Fast Track Designation to AP-SA02.

AP-SA02 is the company’s intravenously administered multi-phage product for the treatment of complicated bacteremia caused by Staphylococcus aureus. The designation underscores the potential of the candidate drug to improve upon current standards and care of treatment for complicated Staphylococcus aureus bacteremia SAB.

The designation is designed to facilitate and expedite the review of investigational therapies for serious conditions with tremendous potential. It also paves the way for the rolling of a Biologic License Application and eligibility for Accelerated Approval and Priority Review.

Following the designation, Armata Pharmaceutical is poised to pursue a Phase 3 superiority study set for the second half of the year. The company has already entered into a secured credit agreement with Innoviva Strategic Opportunities for a $25 million loan. Proceeds from the transaction will be used to finance the development of AP-SA02.

Armata Pharmaceuticals Inc. (NYSE:ARMP) is a clinical-stage biotechnology company developing precisely targeted, pathogen-specific bacteriophage (phage) therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. Their mission is to combat the global antibiotic resistance crisis while preserving the healthy human microbiome.

11. SKYX Platforms Corp. (NASDAQ:SKYX)

Market Capitalization: $145.76 Million

Expected 5-Year Earnings Growth: 68.50%

Number of Hedge Fund Holders: 8

Stock Upside Potential: 324.53%

SKYX Platforms Corp (NASDAQ:SKYX) is one of the high-growth micro-cap stocks to buy now. On June 10, SKYX Platforms Corp (NASDAQ:SKYX) confirmed it is poised to deploy its advanced smart technologies as part of a comprehensive renovation of The Mozart Prague, an iconic 5-star hotel in the Czech Republic.

SKYX Platforms Corp is to supply its advanced smart plug-and-play technologies, including ceiling lighting, ceiling fans, emergency lights, and outdoor lights, among others. The integration of technologies is expected to improve the quality of life and safety standards in hotels and buildings, while also reducing costs.

Similarly, SKYX Platforms has also inked a licensing agreement with lighting company Eurofase to distribute its ceiling electrical outlets and smart home technologies across the builder and commercial segments. Eurofase is to incorporate the company’s ceiling electrical outlet technology into its product offerings that it currently distributes in the US, Canada, Europe, and Asia.

SKYX Platforms Corp. (NASDAQ:SKYX) is a technology company specializing in plug-and-play platform technologies that make electrical installations such as light fixtures and ceiling fans safer and smarter. Their core mission is to establish enhanced safety and intelligence as the new standard for homes and buildings.

10. Insight Molecular Diagnostics Inc. (NASDAQ:IMDX)

Market Capitalization: $183.41 Million

Expected 5-Year Earnings Growth: 21.77%

Number of Hedge Fund Holders: 8

Stock Upside Potential: 87.17%

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is one of the high-growth micro-cap stocks to buy now. On June 11, Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) announced the online publication in the American Journal of Transplantation of new data demonstrating the statistical superiority of its flagship GraftAssure transplant rejection monitoring assay. The study showed that the novel GraftAssure Combination Model (CM)‑score, which integrates relative and absolute DNA fragment measurements, strongly correlates with kidney transplant rejection, confirming its reliability over non‑rejection cases.

First presented at the World Transplant Congress in 2025, the findings highlight the assay’s potential to help physicians distinguish rejection from other causes of organ damage, offering unprecedented diagnostic power. The data and its implications will be further discussed at the American Transplant Congress in Boston from June 20–24, 2026.

Meanwhile, BTIG reiterated its Neutral rating on May 15, awaiting FDA approval of GraftAssureDx, the company’s test kit designed to expand access to kidney transplant monitoring in a $2 billion‑plus market. With faster turnaround times and international appeal, GraftAssureDx could be transformative, though competition from established lab testing firms and the need to strengthen global strategy remain challenges.

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is a precision diagnostics company that develops and commercializes blood-based tests, laboratory services, and testing kits. Their primary focus is democratizing molecular diagnostic testing in transplant care and oncology.

9. Arbe Robotics Ltd. (NASDAQ:ARBE)

Market Capitalization: $112.83 Million

Expected 5-Year Earnings Growth: 39.68%

Number of Hedge Fund Holders: 8

Stock Upside Potential: 70.90%

Arbe Robotics Ltd. (NASDAQ:ARBE) is a high-growth micro-cap stock to buy now. On May 28, Arbe Robotics (NASDAQ:ARBE) president and co-founder Kobi Marenko reiterated that the company is broadening from a pure-play automotive chipset company to a supplier of complete radar solutions.

The sentiments came on the heels of solid first-quarter results that underscored robust growth in the core business. Q1 2026 revenues rose to $0.5 million, up from $0.04 million in Q1 2025. The company also exited the quarter with a backlog of $1 million. Net loss in the quarter shrank to $9.4 million compared to a net loss of $13.8 million delivered last year in the same quarter.

During the quarter, Arbe Robotics received additional orders from global robotaxi players to support L4 autonomy with 360-degree sensing. The company also began shipping chipsets to Hirain for its L4 project. Hirain is using Arbe’s chipset for a high-resolution 48×48 imaging radar project and is expected to expand the company’s reach in China with a new 24×12-channel radar platform.

Arbe Robotics Ltd. (NASDAQ:ARBE) develops ultra-high-resolution 4D imaging radar technology for the automotive industry. Their technology allows vehicles to accurately perceive their surroundings in all weather conditions, making advanced driver-assist systems (ADAS) and autonomous vehicles safer and more reliable.

8. Draganfly Inc. (NASDAQ:DPRO)

Market Capitalization: $223.20 Million

Expected 5-Year Earnings Growth: 29.47%

Number of Hedge Fund Holders: 9

Stock Upside Potential: 104.17%

Draganfly Inc. (NASDAQ:DPRO) is one of the high-growth micro-cap stocks to buy now. On June 11, Draganfly Inc. (NASDAQ:DPRO) confirmed it has completed the acquisition of Skip Dynamix Corporation for an aggregate purchase price of up to $7.525 million.

Under the terms of the agreement, $2.525 million was paid at closing, and $2.5 million in Draganfly shares, valued at $6.46 per share. The remaining $2.5 million is tied to earn-out consideration. With the acquisition, Draganfly has expanded and strengthened its defense platform portfolio. Consequently, it is well positioned to pursue opportunities around the US Department of War and NATO-aligned modernization initiatives.

The company has also strengthened its position with rapidly growing low-cost autonomous aerial systems. Draganfly plans to integrate Skip Dynamix technologies into its broader defense ecosystem, which includes AI-enabled autonomy, sensor integration, and next-generation mission systems. The combination is also expected to offer significant revenue synergies and enable incremental revenue growth.

Draganfly Inc. (NASDAQ:DPRO) is a long-standing developer and manufacturer of professional, unmanned aerial vehicles (UAVs), software, and AI systems. They provide custom engineering, flight training, and data collection services for enterprise, defense, civil, and public safety markets.

7. Aviat Networks Inc. (NASDAQ:AVNW)

Market Capitalization: $268.17 Million

Expected 5-Year Earnings Growth: 20.88%

Number of Hedge Fund Holders: 14

Stock Upside Potential: 50.75%

Aviat Networks Inc. (NASDAQ:AVNW) is a high-growth micro-cap stock to buy now. On May 26, Aviat Networks Inc. (NASDAQ:AVNW) hit a new milestone following the expansion of its all-indoor microwave platform.

The expanded platform now combines Pasolink and IRU600 products. The integration results in a significant upgrade in capacity and reliability for North American Customers. It also introduces Pasolink LH, a new long-haul solution for targeting international trunking and backbone markets.

The all-indoor solution will keep all active equipment protected inside a shelter, reducing operational expenditure. It will also eliminate the need to climb towers to add capacity or upgrade features. The architecture in place has always been the backbone of communications networks worldwide.

Customers can now benefit from the combination of high-capacity Pasolink IP networking and Aviat’s indoor and outdoor radios. With the expanded all-indoor microwave platforms, Aviat Networks remains well positioned to target an incremental addressable market valued at over $250 million.

Aviat Networks Inc. (NASDAQ:AVNW) is a global provider of wireless transport and microwave networking solutions. They design, manufacture, and deploy advanced equipment that enables reliable, high-capacity connections for mobile operators, rural broadband providers, governments, and utilities—often serving as a faster, more cost-effective alternative to laying traditional fiber.

6. Apyx Medical Corporation (NASDAQ:APYX)

Market Capitalization: $204.47 Million

Expected 5-Year Earnings Growth: 26.64%

Number of Hedge Fund Holders: 15

Stock Upside Potential: 27.93%

Apyx Medical Corporation (NASDAQ:APYX) is one of the high-growth micro-cap stocks to buy now. On May 21, Apyx Medical Corporation (NASDAQ:APYX) announced new clinical data in Aesthetic Surgery Journal Open Forum highlighting a promising approach to treating cellulite and skin laxity, two common concerns among women.

The results were part of a clinical study evaluating a combination treatment approach utilizing Avéli for targeted subcision to disrupt fibrous septae, followed by Renuvion to reduce skin laxity. The study was conducted through controlled helium plasma radiofrequency energy.

Conducted in 22 patients, the study showed that 81.8% of patients improved cellulite, with 3D imaging demonstrating measurable reductions in dimple volume. The study results affirmed that a combination of Aveli and Renuvion is effective in addressing the structural cause of dimpling and the quality of the skin itself. According to Barry E. DiBernardo, MD, lead investigator of the study, the findings add to growing evidence that affirms complementary treatment approaches.

Apyx Medical Corporation (NASDAQ:APYX) is an advanced energy technology company that develops, manufactures, and markets medical devices for the cosmetic and surgical markets. They are best known for their proprietary Helium Plasma Technology, which provides surgeons with highly precise, controlled heat for cutting, coagulating, and contracting soft tissue.

Click to continue reading and see the 5 High-Growth Micro-Cap Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.